Oppenheimer starts coverage of PolyPid with Outperform rating and $10 price target
Oppenheimer began coverage of PolyPid Ltd., assigning an Outperform rating and a $10.00 price target. The firm highlighted the D‑PLEX100 depot, which cut surgical site infections by roughly 60% in a Phase 3 sub‑group study and is under FDA Priority Review. PolyPid reported a second‑quarter 2026 loss of $0.35 per share, better than the $0.40 loss analysts had expected. The company will commercialize D‑PLEX100 in the United States and Canada through a partnership with Azurity, earning tiered royalties in the mid‑teens to mid‑20s percent plus a per‑vial transfer price.
Why it matters
Oppenheimer’s initiation and $10 target suggest upside of about 89% from the current $5.29 price, which could attract buying interest. The narrower loss and progress on D‑PLEX100 may improve the company’s cash‑burn outlook ahead of a 2027 launch.
Key facts
- 1Oppenheimer initiated coverage with an Outperform rating and a $10.00 price target. investing.com
- 2PolyPid’s shares were trading at $5.29 at the time of the report. investing.com
- 3The stock had risen 47% over the past year. investing.com
- 4PolyPid reported a Q2 2026 loss of $0.35 per share, beating the expected loss of $0.40 per share. investing.com
- 5D‑PLEX100 reduced surgical site infections by approximately 60% in a Phase 3 sub‑group study. investing.com
- 6The product is under FDA Priority Review with a PDUFA date of November 28, 2026. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.